Our data indicate defects in TEC activation in DS due to attenuation of the CaN–NFAT pathway by chromosome 21-encoded inhibitors of this pathway preventing transactivation of the NFAT-dependent target, GDNF. The gene discussed is GDNF; the disease is Dravet syndrome.